Puma Biotech (PBYI) Tops Q1 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Puma Biotechnology Reports First Quarter 2016 Financial Results
May 10, 2016 4:17 PM EDTLOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.
Unless otherwise stated, all comparisons are for the first quarter 2016 compared to the first quarter 2015.
Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss applicable to common stock of $71.0 million, or $2.19 per share, for the first quarter of 2016, compared to a net loss applicable to common stock of $52.5 million, or $1.66 per share, for the first quarter of 2015.
Non-GAAP adjusted net loss was $41.5... More
